ONCY insider buying & filings

← All candidates

ONCYONCOLYTICS BIOTECH INC

NasdaqCM · Healthcare · $107.31M

$0.8050

-3.70% · Sep 15

Twelve insider buys in the last year — $347.5K in all.
Nothing in the last fortnight.

Last Form 4 Feb 13 · scanned 22m ago

Price · 1Y · daily● 12 buys◆ 14 8-K

▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained

Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what ONCY ever actually traded at. The drop is real, but those huge old numbers aren't.

AI brief · from the filings on this pagePro

The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.

▸ Included with Pro →

Market cap

$107.31M

Float

116.9M

98% public

Short % float

Pro

The buyers

▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions

Director

Seizinger Bernd R.

Bought $103.8K on Jan 16 — 100,000 sh @ $1.04, held direct, 21% of their stake.

0 of 1 position beat the S&P

median -20.3% vs S&P +10.7% same spans · 3 buy-days

Director

Andrews Patricia S

Bought $30.3K on Feb 12 — 35,400 sh @ $0.8557, held direct, 45% of their stake.

First Form 4 on file

no positions we can measure against the market — the record starts here

Chief Business Officer

Aromando Andrew

Bought $25.4K on Feb 11 — 29,600 sh @ $0.8587, held direct, 54% of their stake.

First Form 4 on file

no positions we can measure against the market — the record starts here

The record

newest first

DateTypeInsiderOf stakeShares @ priceValue

Feb 13BUYSeizinger Bernd R.Director+7.1%direct40,000 @ $0.8466$33.9K

Feb 13BUYPisano WayneDirector+6.1%direct30,000 @ $0.8446$25.3K

Feb 13BUYLook KirkChief Financial Officer+4.2%direct12,000 @ $0.8420$10.1K

Feb 13BUYKelly JaredChief Executive Officer+27%direct29,500 @ $0.8420$24.8K

Feb 13BUYHeineman Thomas CharlesChief Medical Officer+4.3%direct12,132 @ $0.8270$10.0K

7 more transactions on Pro →

Context

Wall St

$4.92 avg target

+511.2% vs today · 6 analysts

▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice

Earnings · EPS vs forecast

1 of 3 quarters beat

Q1 '26−$0.11 act−$0.04

Q3 '25−$0.14 act−$0.07

Q2 '25−$0.07 act+$0.01

Coverage

ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For OncolyticsStocktwits · 06-16 Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor AttentionSimply Wall St. · 06-04 ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment StudyStocktwits · 06-01 Oncolytics Biotech Reports Data in Colorectal Cancer StudyIPO-Edge.com · 05-06

The file stays open

14 filings on record.
The next one will be too.

All candidates

▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice

Seizinger Bernd R.

Andrews Patricia S

Aromando Andrew

14 filings on record.The next one will be too.

14 filings on record.
The next one will be too.